Neue Novavax: Anstieg nach 1:20 Re-Split


Seite 1 von 4
Neuester Beitrag: 26.03.20 15:55
Eröffnet am: 15.05.19 08:23 von: moneywork4. Anzahl Beiträge: 97
Neuester Beitrag: 26.03.20 15:55 von: Banani Leser gesamt: 9.742
Forum: Hot-Stocks   Leser heute: 24
Bewertet mit:
2


 
Seite: < 1 | 2 | 3 | 4 4  >  

289 Postings, 331 Tage moneywork4meNeue Novavax: Anstieg nach 1:20 Re-Split

 
  
    #1
2
15.05.19 08:23
Bemerkenswerter Anstieg nach dem Re-Split 1:20
7,13USD        +1,37USD     +23,78% mit entsprechendem Volumen:

Volumen (Stück) 1.262.067

Die Amis sprechen von Schnäppchenjäger
https://seekingalpha.com/news/...gain-hunters-jump-novavax-28-percent

About

https://novavax.com/  
71 Postings ausgeblendet.
Seite: < 1 | 2 | 3 | 4 4  >  

206 Postings, 379 Tage BananiDRAFT landscape of COVID-19 candidate vaccines

 
  
    #73
01.03.20 08:39
These landscape documents have been prepared by the World Health Organizati­on (WHO) for informatio­n purposes only concerning­ the 2019-2020 global of the novel coronaviru­s

https://www.who.int/blueprint/priority-diseases/...cape-ncov.pdf?ua=1  

206 Postings, 379 Tage BananiFDA Issues New Policy to Help Expedite...

 
  
    #74
01.03.20 09:17
FDA Issues New Policy to Help Expedite Availability of Diagnostics

https://www.fda.gov/news-events/...-expedite-availability-diagnostics  

17698 Postings, 3643 Tage Balu4utaucht ab

 
  
    #75
02.03.20 15:36
https://old.nasdaq.com/de/symbol/nvax/real-time  

206 Postings, 379 Tage BananiSpiele der Amis beginnen, imho.

 
  
    #76
02.03.20 15:41
 

583 Postings, 1511 Tage Dawnrazor-23%

 
  
    #77
02.03.20 15:43
Handel für Novavax war eben für kurze Zeit sogar angehalten.  

206 Postings, 379 Tage BananiNovavax capitalizing on stock bump following...

 
  
    #78
03.03.20 06:31
Novavax capitalizing on stock bump following coronavirus vaccine news.

The Gaithersburg biotech has raked in $98.7 million in net proceeds this quarter from selling 10.5 million shares of common stock at $9.55 per share....


https://www.bizjournals.com/washington/news/2020/...oo&yptr=yahoo  

1113 Postings, 1256 Tage Unicorn71Hatte einen Sprung nach oben erwartet...

 
  
    #79
03.03.20 08:33
Nachdem Novavax zu den auserwählten Unternehmen gehören, die von Trump im Weißen Haus empfangen wurden, um über Corona zu beraten. War immerhin ne illustre Runde mit J&J, Sanofi, Gilead (Forty Seven), ect...  

17698 Postings, 3643 Tage Balu4uWeiter down...

 
  
    #80
03.03.20 12:41
https://old.nasdaq.com/de/symbol/nvax/real-time  

206 Postings, 379 Tage BananiVideo: Ab 34:50min spricht Stanley C. Erck

 
  
    #81
1
03.03.20 20:10
President Trump Meeting With Pharmaceutical Executives on Coronavirus

https://www.c-span.org/video/?469926-1/...ical-executives-coronavirus  

206 Postings, 379 Tage BananiEin Kommentar aus dem Yahoo Finance Forum:

 
  
    #82
08.03.20 09:25
We didn't invest in Novavax for the Coronavirus. I could care less. Nanoflu destroyed Fluzone HD in phase 2 so Phase 3 should be a cake walk. What can actually change in the results? The Nanoparticle with the Matrix M adjuvant is a powerhouse! I'm going to say this. Novavax has created a WORLDWIDE well needed flu drug! $12.48? This is like free money! Invest invest and invest! Less than 30 days the ROI will be outstanding.

Ich lehne mich jetzt mal weit aus dem Fenster und sage, genau so wird es kommen, imho.
 

4286 Postings, 1528 Tage aktienpowerÜbersetzung

 
  
    #83
08.03.20 14:27


Kommentar aus dem Yahoo Finance Forum: Wir haben nicht in Novavax für das Coronavirus investiert. Es könnte mich weniger interessieren. Nanoflu zerstörte Fluzone HD in Phase 2, daher sollte Phase 3 ein Kinderspiel sein. Was kann sich tatsächlich an den Ergebnissen ändern? Das Nanopartikel mit dem Matrix M-Adjuvans ist ein Kraftpaket! Ich werde das sagen. Novavax hat ein weltweit benötigtes Grippemedikament entwickelt! 12,48 $? Das ist wie freies Geld! Investieren investieren und investieren! In weniger als 30 Tagen ist der ROI hervorragend.  

3 Postings, 23 Tage MiniOhEinschätzung

 
  
    #84
08.03.20 17:55
Hier mal noch eine Einschätzung von heute von Keith Speights
(TMFFishBiz):

"There's no way to know for sure which of these biotech stocks will be the bigger winner over the long run. If I had to pick just one of them, though, it would be Novavax.

Inovio does appear to have a slight lead with its coronavirus program. However, Novavax has a major catalyst coming up in a matter of weeks with the announcement of results for NanoFlu. My view is that Novavax has a reasonable chance of getting a product on the market much sooner than Inovio does.

Keep in mind, though, that both of these stocks are very risky. Their experimental COVID-19 vaccines and their other pipeline candidates could flop in clinical studies. While I think Novavax has the edge right now, it's best to be very cautious when investing in clinical-stage biotechs."  

Optionen

4286 Postings, 1528 Tage aktienpowerÜbersetzung

 
  
    #85
08.03.20 18:07


Es ist nicht sicher, welche dieser Biotech-Aktien auf lange Sicht der größere Gewinner sein wird. Wenn ich nur einen auswählen müsste, wäre es Novavax. Inovio scheint mit seinem Coronavirus-Programm einen leichten Vorsprung zu haben. Novavax hat jedoch innerhalb weniger Wochen mit der Bekanntgabe der Ergebnisse für NanoFlu einen wichtigen Katalysator vor sich. Meiner Ansicht nach hat Novavax eine vernünftige Chance, ein Produkt viel früher auf den Markt zu bringen als Inovio. Beachten Sie jedoch, dass beide Aktien sehr riskant sind. Ihre experimentellen COVID-19-Impfstoffe und ihre anderen Pipeline-Kandidaten könnten in klinischen Studien versagen. Ich denke, Novavax hat momentan die Nase vorn, aber es ist am besten, sehr vorsichtig zu sein, wenn Sie in Biotech-Unternehmen im klinischen Stadium investieren.  

206 Postings, 379 Tage BananiNovavax Awarded Funding from CEPI for COVID-19...

 
  
    #86
10.03.20 12:18
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

-CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1

-Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials

-Phase 1 clinical trial expected to initiate in late spring of 2020

http://ir.novavax.com/news-releases/...i-covid-19-vaccine-development  

3402 Postings, 683 Tage AhorncanBevor geimpft wird....

 
  
    #87
10.03.20 18:23
muss erstmal getestet werden. Und das macht nun NanoRepro....  

206 Postings, 379 Tage BananiNovavax and Serum Institute of India to Develop...

 
  
    #88
11.03.20 18:46
 

206 Postings, 379 Tage BananiNovavax and Serum Institute of India to....

 
  
    #89
11.03.20 18:46
Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

https://finance.yahoo.com/news/...titute-india-develop-144548684.html  

206 Postings, 379 Tage BananiNeues Kursziel von Oppenheimer $18

 
  
    #90
11.03.20 21:21
Oppenheimer Backs Novavax as a Coronavirus Play

https://finance.yahoo.com/news/...vax-coronavirus-play-190117201.html  

206 Postings, 379 Tage BananiEnde März sollten die Ergebnisse kommen

 
  
    #91
24.03.20 12:20
und da sind sie:

Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults.

http://ir.novavax.com/news-releases/...ary-endpoints-phase-3-clinical  

10766 Postings, 3586 Tage sonnenscheinchenspannender noch wäre die Frage, ob Nanoflu

 
  
    #92
24.03.20 12:25
mit seinem breiten Profil nicht auch gegen Coronaviren funktioniert ^^  

206 Postings, 379 Tage BananiAllein der Vergleich zu Fluzone ist grandios.

 
  
    #93
24.03.20 12:46
Jetzt kommt es auf das Management an alle weiteren Schritte richtig zu wählen.  

2131 Postings, 4044 Tage MagnetfeldfredyNovavax, best in class mit meets primary endpoints

 
  
    #94
25.03.20 13:55
Novavax price target raised to $24 from $17 at H.C. Wainwright 07:26 NVAX H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Novavax to $24 from $17 and reiterates a Buy rating on the shares. The stock closed Tuesday up 19% to $12.77. Novavax yesterday announced positive top-line results from its pivotal Phase 3 clinical trial with NanoFlu, the company's Matrix-M adjuvanted recombinant quadrivalent seasonal influenza vaccine candidate for adults aged 65 and older, Bernardino tells investors in a research note. The results are impressive, as they clearly show better immunogenic responses are stimulated by NanoFlu versus the market-leading quadrivalent seasonal influenza vaccine, says the analyst. Bernardino believes the data create a clear path to FDA licensure.

Read more at:
https://thefly.com/landingPageNews.php?id=3059689  

2131 Postings, 4044 Tage MagnetfeldfredyNovavax, best in class mit meets primary endpoints

 
  
    #95
25.03.20 13:59
Novavax price target raised to $23 from $16 at Cantor Fitzgerald

Read more at:
https://thefly.com/landingPageNews.php?id=3059696  

2131 Postings, 4044 Tage MagnetfeldfredyNovavax Übernahmekandidat nach best in class

 
  
    #96
26.03.20 15:03
Novavax plans FDA filing after NanoFlu trumps Sanofi flu vaccine
26th March 2020
Image


by

Anna Smith

Novavax has unveiled new Phase III data showing that its recombinant quadrivalent seasonal influenza vaccine candidate, NanoFlu, met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent.

As a results of the successful data, the company has announced plans to submit a filing to the US Food and Drug Administration (FDA) under the agency's accelerated approval pathway.

In the trial, geometric mean titers (GMT) at day 28 for NanoFlu were 24% to 66% higher than for Fluzone Quadrivalent, while the experimental vaccine was associated with 11.4 to 20.4 higher seroconversion rates (SCR) percentage points than the Sanofi drug.

Top-line results showed that NanoFlu achieved the primary endpoints, using both GMT and SCR, for all four strains included in the vaccine, as measured by haemagglutination inhibition (HAI) assays using egg-derived reagents.

According to the company, NanoFlu was also well tolerated in the Phase III study and had a safety profile comparable to Fluzone Quadrivalent, but was associated "with a modest increase in local adverse events."

Last year Novavax announced that its respiratory syncytial virus vaccine ResVax failed to hit its main goal, despite showing efficacy against a secondary objective, preventing RSV LRTI hospitalisations by 44%.
Share
 

206 Postings, 379 Tage BananiMagnetfeldfredy, definitiv Übernahmekandidat

 
  
    #97
26.03.20 15:55
 

Seite: < 1 | 2 | 3 | 4 4  >  
   Antwort einfügen - nach oben